3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
52
Prostatic Neoplasms
23
Lung Neoplasms
17
Breast Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
14
Stomach Neoplasms
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Neoplasms
9
Urinary Bladder Neoplasms
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma, Transitional Cell
6
Triple Negative Breast Neoplasms
5
Non-Muscle Invasive Bladder Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Squamous Cell
5
Prostatic Neoplasms, Castration-Resistant
4
Ovarian Neoplasms
4
Oropharyngeal Neoplasms
4
Small Cell Lung Carcinoma
3
Salivary Gland Neoplasms
3
Nasopharyngeal Carcinoma
3
Laryngeal Neoplasms
3
HER2-positive Breast Cancer
3
Fallopian Tube Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Anatomic Stage I Breast Cancer AJCC v8
3
Adenocarcinoma
3
Vaccinia
2
Interventions
pembrolizumab
1
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paroxetine
1
Paclitaxel
1
Itraconazole
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
Docetaxel
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled